Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Consumer loyalty driven by aesthetics over functionality

  • When pursuing goals, people give more weight to progress than setbacks

  • Herd mentality: Are we programmed to make bad decisions?

  • Growing shortage of stroke specialists seen in U.S.

  • Electronic cigarettes facilitate smoking cessation, new evidence shows

  • Severely mentally ill criminals: who goes to prison and who goes to psych institutions?

  • Bugs life: The nerve cells that make locusts ?gang up?

  • Firearm violence trends in the 21st century

  • Personality outsmarts intelligence at school: Conscientiousness and openness key to learning

  • Women are more empathetic toward their partner than men

  •